Current status of long-term follow-up system for women with a history of hypertensive disorders of pregnancy: the HDP-PPAP study (HDP-Postpartum in Aomori prefecture study)

Figures & data

Figure 1. Long-term follow-up system for woman with HDP.

Table 1. Demographic characteristics of the study population.

Characteristics	N = 92
Age at delivery (year)	34.8 ± 4.5
BMI before pregnancy (㎏/m²)	23.6 ± 4.8
Weight gain during pregnancy (㎏)	8.4 ± 4.5
Smoking	3 (3.2％)
Hypertension	9 (9.8％)
Diabetes mellitus	6 (6.5％)
Renal disease	3 (3.2％)
Primipara	58 (63.0％)
Singleton pregnancy	82 (89.1％)
Natural Pregnancy	48 (52.2％)
Delivery method
Spontaneous delivery	30 (32.6％)
Vacuum delivery	20 (21.7％)
Selective cesarean section	14 (15.2％)
Emergency cesarean section	28 (30.4％)
Week of delivery	38.3 ± 2.1
Birth weight of infant (g)	2,744.3 ± 591.1
Amount of blood loss (mL)	769.7 ± 640.4
HDP classification
PE	29 (31.5％)
GH	51 (55.4％)
CH	9 (9.8％)
SPE	3 (3.2％)
Early onset	5 (5.4％)

Values are presented as the mean ± standard deviation or as a number (percentage).

Abbreviation: BMI: Body mass index; PE: Preeclampsia; GH: Gestational hypertension; CH: Chronic hypertension;

SPE: Superimposed preeclampsia.

Figure 2. Number of new cases of lifestyle-related disease in the first and third years postpartum.

Table 2. Comparison of blood pressure levels, BMI, and blood and urine test results at 1 and 3 years postpartum.

	After 1 year	After 3 years	p value
Systolic blood pressure (mmHg)	126.0 (115.8–134.3)	127.0 (116.3–132.8)	0.788
Diastolic blood pressure (mmHg)	78.0 (72.8–87.0)	79.0 (72.0–85.0)	0.231
BMI (kg/m2)	22.6 (20.1–26.4)	22.9 (20.2–27.8)	<0.01
Fasting blood glucose (mg/dL)	96.0 (89.0–102.0)	93.0 (89.5–100.0)	0.591
GA (%)	13.5 (12.9–14.3)	13.6 (12.7–14.6)	0.490
HbA1c (%)	5.4 (5.2–5.6)	5.4 (5.2–5.7)	0.298
Total cholesterol (mg/dL)	187.0 (166.0–216.0)	183.0 (160.0–199.8)	0.104
Triglycerides (mg/dL)	62.0 (48.0–95.0)	70.5 (49.5–108.3)	0.444
Low density lipoprotein cholesterol (mg/dL)	104.5 (90.0–125.8)	103.5 (83.3–122.8)	0.198
High density lipoprotein cholesterol (mg/dL)	60.9 (49.9–69.8)	57.9 (51.1–70.1)	0.227
LDL/HDL	1.8 (1.4–2.3)	1.9 (1.2–2.5)	0.936
BUN (mg/dL)	11.0 (9.0–13.0)	11.0 (9.0–13.0)	0.421
Serum creatinine (mg /dL)	0.59 (0.54–0.65)	0.61(0.56–0.65)	<0.01
eGFR (mL/min per 1.73 m^2)	91.9 (82.2–102.4)	84.9 (79.1–97.1)	<0.01
eGFR PE	95.6 (81.1–102.9)	83.8 (80.0–98.5)	<0.01
eGFR GH	89.08 (1.5–101.1)	84.9 (76.5–97.1)	<0.01
eGFR CH	104.0 (93.6–122.8)	104.9 (70.1–117.9)	0.655
eGFR SPE	90.3 (79.6–96.2)	88.4 (63.2–93.4)	0.441
AST (U/L)	17.0 (15.0–19.0)	18.0 (15.0–20.0)	0.059
ALT (U/L)	14.0 (11.0–21.0)	14.0 (11.0–20.0)	0.863
LDH (U/L)	157.0 (145.8–173.3)	156.0 (144.0–172.5)	0.714
Γ-GTP (U/L)	13.0 (10.0–20.0)	15.5 (12.0–24.3)	<0.01
UA (mg/dL)	4.5 (3.9–5.1)	4.5 (3.8–5.5)	0.301
Urine protein positive	4	1	0.161
Urine glucose positive	2	2	0.567
Urinary microalbumin	0.7 (0.3–1.4)	0.8 (0.4–1.2)	0.090

Values are presented as the median (interquartile range [IQR])or as number.

Abbreviation: AST: Aspartate transferase; ALT: Alanine transaminase; BUN: BMI, Body mass index; GA: glycoalbumin; LDH: LDL: Low density lipoprotein cholesterol; HDL: High density lipoprotein cholesterol; eGFR: estimated glomerular filtration rate; UA: Uric Acid; PE: Preeclampsia; Γ-GTP, GH: Gestational hypertension; CH: Chronic hypertension; SPE: Superimposed preeclampsia.